Primary Site >> Colorectal Cancer

Gene >> PROK1

Journal: Clin Cancer Res. 1999 Jan;5(1):83-94.
Title: Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.
Author: Vasey, P A|Kaye, S B|Morrison, R|Twelves, C|Wilson, P|Duncan, R|Thomson, A H|Murray, L S|Hilditch, T E|Murray, T|Burtles, S|Fraier, D|Frigerio, E|Cassidy, J
PMID: 9918206
Journal: Eur J Nutr. 1999 Jun;38(3):133-42.
Title: Comparative analysis of the effects of flavonoids on proliferation, cytotoxicity, and apoptosis in human colon cancer cell lines.
Author: Kuntz, S|Wenzel, U|Daniel, H
PMID: 10443335
Journal: Curr Opin Mol Ther. 2003 Jun;5(3):326-30.
Title: Technology evaluation: PK1, Pfizer/Cancer Research UK.
Author: Bilim, Vladimir
PMID: 12870445
Journal: Cancer Res. 2004 Mar 15;64(6):1906-10.
Title: Angiogenesis and tumor proliferation/metastasis of human colorectal cancer cell line SW620 transfected with endocrine glands-derived-vascular endothelial growth factor, as a new angiogenic factor.
Author: Goi, Takanori|Fujioka, Masako|Satoh, Yoshiki|Tabata, Shinsuke|Koneri, Kenji|Nagano, Hideki|Hirono, Yasuo|Katayama, Kanji|Hirose, Kazuo|Yamaguchi, Akio
PMID: 15026321
Journal: J Surg Oncol. 2007 Dec 1;96(7):605-10.
Title: Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) expression in colorectal cancer.
Author: Nagano, Hideki|Goi, Takanori|Koneri, Kenji|Hirono, Yasuo|Katayama, Kanji|Yamaguchi, Akio
PMID: 17786959
Journal: Int J Oncol. 2009 Jun;34(6):1629-36.
Title: Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.
Author: Seymour, Leonard W|Ferry, David R|Kerr, David J|Rea, Daniel|Whitlock, Maggie|Poyner, Richard|Boivin, Christopher|Hesslewood, Stuart|Twelves, Christopher|Blackie, Robert|Schatzlein, Andreas|Jodrell, Duncan|Bissett, Donald|Calvert, Hilary|Lind, Mike|Robbins
PMID: 19424581
Journal: Oncol Rep. 2013 Feb;29(2):459-63.
Title: Endocrine gland-derived vascular endothelial growth factor strengthens cell invasion ability via prokineticin receptor 2 in colon cancer cell lines.
Author: Tabata, Shinsuke|Goi, Takanori|Nakazawa, Toshiyuki|Kimura, Youhei|Katayama, Kanji|Yamaguchi, Akio
PMID: 23135359
Journal: Anticancer Res. 2013 Dec;33(12):5311-5.
Title: Prokineticin 1 expression in gastrointestinal tumors.
Author: Goi, Takanori|Nakazawa, Toshiyuki|Hirono, Yasuo|Yamaguchi, Akio
PMID: 24324064
Journal: Ann Surg Oncol. 2014 Dec;21 Suppl 4:S665-71.
Title: Anti-prokineticin1 (PROK1) monoclonal antibody suppresses angiogenesis and tumor growth in colorectal cancer.
Author: Goi, Takanori|Nakazawa, Toshiyuki|Hirono, Yasuo|Yamaguchi, Akio
PMID: 24838366
Journal: Ann Surg Oncol. 2015 May;22(5):1496-503.
Title: Prokineticin 1 protein expression is a useful new prognostic factor for human sporadic colorectal cancer.
Author: Nakazawa, Toshiyuki|Goi, Takanori|Hirono, Yasuo|Yamaguchi, Akio
PMID: 25331005
Journal: Oncotarget. 2015 Mar 20;6(8):6053-61.
Title: The anti-tumor effect is enhanced by simultaneously targeting VEGF and PROK1 in colorectal cancer.
Author: Goi, Takanori|Nakazawa, Toshiyuki|Hirono, Yasuo|Yamaguchi, Akio
PMID: 25788276
Journal: Oncotarget. 2015 Oct 6;6(30):28790-9.
Title: The prognosis was poorer in colorectal cancers that expressed both VEGF and PROK1 (No correlation coefficient between VEGF and PROK1).
Author: Goi, Takanori|Nakazawa, Toshiyuki|Hirono, Yasuo|Yamaguchi, Akio
PMID: 26318037
Journal: Cancer Biomark. 2018 Feb 6;21(2):345-354.
Title: Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) and its receptor PROKR2 are associated to human colorectal cancer progression and peritoneal carcinomatosis.
Author: Benlahfid, Mohammed|Traboulsi, Wael|Sergent, Frederic|Benharouga, Mohamed|Elhattabi, Khalid|Erguibi, Driss|Karkouri, Mehdi|Elattar, Hicham|Fadil, Abdelaziz|Fahmi, Yassine|Aboussaouira, Touria|Alfaidy, Nadia
PMID: 29226856